Pricing Log in Create free account

Neurocrine Biosciences, Inc. (NBIX) vs Zoetis Inc. (ZTS)

Neurocrine Biosciences, Inc. and Zoetis Inc. are both Drug Manufacturers Specialty & Generic companies. Zoetis Inc. is the larger, with a market value of $32.4B against $13.9B — 2.3× the size. Zoetis Inc. trades at the lower P/E: 13.0× against 19.2×. Neurocrine Biosciences, Inc. grew revenue faster over the last twelve months: 34.4% against 1.58%. Zoetis Inc. has the higher net margin (27.7% vs 20.9%) and the higher return on invested capital (19.6% vs 15.0%). Across the 22 metrics below, Zoetis Inc. leads on 13 and Neurocrine Biosciences, Inc. on 9.

Valuation

Metric NBIX ZTS Drug Manufacturers Specialty & Generic median
P/E 19.25 13.03 19.25
P/S 4.06 3.47 2.11
P/B 3.71 10.51 1.78
Price to free cash flow 15.75 14.21 16.14
EV/EBITDA 16.66 10.40 12.58
EV/Sales 4.11 4.39 2.73
Earnings yield 5.19% 7.68% (4.38%)
Free cash flow yield 6.35% 7.04% 0.00%

Profitability

Metric NBIX ZTS Drug Manufacturers Specialty & Generic median
Gross margin 97.94% 71.67% 53.94%
Operating margin 23.56% 37.13% 0.00%
Net margin 20.91% 27.69% 0.00%
Free cash flow margin 25.80% 24.43% 0.00%
Return on equity 22.09% 64.91% (0.40%)
Return on assets 15.26% 17.84% (3.32%)
Return on invested capital 15.04% 19.60% 0.00%

Growth

Metric NBIX ZTS Drug Manufacturers Specialty & Generic median
Revenue growth (TTM) 34.42% 1.58% 10.01%
EPS growth (last fiscal year) 41.95% 10.05% 49.06%
Revenue growth, 5-year CAGR 22.29% 7.24% 6.74%
Net income growth, 5-year CAGR 3.28% 10.29% 0.00%

Health

Metric NBIX ZTS Drug Manufacturers Specialty & Generic median
Debt to equity 0.00 2.87 0.05
Current ratio 1.87 3.08 2.31
Net debt to EBITDA (2.33) 1.65 0.97

Dividend

Metric NBIX ZTS Drug Manufacturers Specialty & Generic median
Dividend yield — 2.64% 1.57%
Payout ratio — 0.34 0.27

Size

Metric NBIX ZTS Drug Manufacturers Specialty & Generic median
Market cap 13.92b 32.40b 276.90m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack